

Appendix 4E

Preliminary final report XRF Scientific Limited (ABN: 80 107 908 314) For the period ended 30 June 2025

Note: To be read in conjunction with 2025 Annual Report, lodged on the same date as this document.

1. Details of the reporting period and the previous corresponding period:
Reporting period – 12-month period ended 30 June 2025
Previous corresponding period – 12-month period ended 30 June 2024

2. Results for announcement to the market:

- 2.1 Revenue from ordinary activities:

30 June 2025	30 June 2024	% change
\$59,448,334	\$60,116,820	- 1%

- 2.2 Profit from ordinary activities after tax attributable to members:

30 June 2025	30 June 2024	% change
\$10,383,453	\$8,885,264	+ 17%

- 2.3 Net profit (loss) for the period attributable to members:

30 June 2025	30 June 2024	% change
\$10,383,453	\$8,885,264	+ 17%

- 2.4 Declared dividends summary:

	30 June 2025	30 June 2024
Final dividend per security	4.5c	3.9c
Franked amount per security	4.5c	3.9c

Note: No interim dividends were paid during the current or previous corresponding periods.

- 2.5 The record date for determining entitlements to the dividends:
12 September 2025

- 2.6 A brief explanation of any of the figures in 2.1 to 2.4 necessary to enable the figures to be understood:

Refer to the OPERATING RESULTS commentary on pages 5 to 6 of the 2025 Annual Report.

3. Statement of comprehensive income together with notes to the statement, prepared in compliance with AASB 101 Presentation of Financial Statements or the equivalent foreign accounting standard:
Refer to the CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME on page 19 of the 2025 Annual Report.

4. Statement of financial position together with notes to the statement:
Refer to the CONSOLIDATED STATEMENT OF FINANCIAL POSITION on page 20 of the 2025 Annual Report.
5. Statement of cash flows together with notes to the statement:
Refer to the CONSOLIDATED STATEMENT OF CASH FLOWS on page 22 of the 2025 Annual Report.
6. Statement of retained earnings, or a statement of changes in equity, showing movements:
Refer to the CONSOLIDATED STATEMENT OF CHANGES IN EQUITY on page 21 of the 2025 Annual Report.

7. Summary of dividends paid/payable during the period:

Paid during period ending	Amount paid per share	Total amount paid/payable	Date paid/payable
30 June 2025	3.9c	\$5,438,237	27 September 2024
30 June 2026	4.5c	\$6,324,124	26 September 2025

8. Dividend reinvestment plan details:
The Company has a dividend reinvestment plan in place and full details are available on the Company's website. Election notices received by the Company's share registry prior to 5.00pm (WST) on the business day following a record date for a particular dividend will be effective in respect of that dividend and all subsequent dividends.

9. Net tangible assets per security:

30 June 2025	30 June 2024
\$0.31	\$0.28

10. Details of entities over which control has been gained or lost during the period, including the following:

- 10.1 Name of the entity:
During the period, XRF Scientific Limited acquired 100% of the shares in Labfit Pty Ltd, a business based in Bayswater, Western Australia.
- 10.2 The date of the gain or loss of control:
12 December 2024
- 10.3 The contribution of entity to the reporting entity's profit from ordinary activities:
The acquired business contributed revenues of \$536k and net profit before tax of \$91k to the group for the period of 12 December 2024 to 30 June 2025. If the acquisition had occurred on 1 July 2024, consolidated revenue and consolidated net profit before tax for the period ended 30 June 2025 would have been \$60.2m and \$14.6m respectively. These amounts have been calculated using the group's accounting policies.

11. Details of associates and joint venture entities including the following:
 - 11.1 Name of the associate or joint venture entity:
Not applicable – There were no associate or joint venture relationships during the current period.
 - 11.2 Details of the reporting entity's percentage holding in each of these entities:
Not applicable – There were no associate or joint venture relationships during the current period.
 - 11.3 Aggregate share of profits (losses) of these entities, details of contributions to net profit for each of these entities, and with comparative figures for each of these disclosures for the previous corresponding period:
Not applicable - There were no associate or joint venture relationships during the current period.
12. Any other significant information needed by an investor to make an informed assessment of the entity's financial performance and financial position.
Refer to the 2025 Annual Report.
14. A commentary on the results for the period:
 - 14.1 The earnings per security and the nature of any dilution aspects:
Refer to the REVIEW OF OPERATIONS on page 5 of the 2025 Annual Report.
 - 14.2 Returns to shareholders including distributions and buy backs:
Refer to the OPERATING RESULTS commentary on pages 5 to 6 of the 2025 Annual Report.
 - 14.3 Significant features of operating performance:
Refer to the OPERATING RESULTS commentary on pages 5 to 6 of the 2025 Annual Report.
 - 14.4 The results of segments that are significant to an understanding of the business as a whole:
Refer to the NOTE 4: SEGMENT INFORMATION on pages 36 to 37 of the 2025 Annual Report.
 - 14.5 A discussion of trends in performance:
Refer to the OPERATING RESULTS commentary on pages 5 to 6 of the 2025 Annual Report.
 - 14.6 Any other factors which have affected the results in the period or which are likely to affect results in the future, including those where the effect could not be quantified:
Refer to the OPERATING RESULTS commentary on pages 5 to 6 of the 2025 Annual Report.
15. This report is based on accounts which have been audited. Refer to the AUDITOR'S REPORT on pages 60 to 63 of the 2025 Annual Report.